The previously announced publication date was 3 June 2026. The new publication date is 10 June 2026.

The annual report will be published on the company’s website as soon as it is finalised.

For further information, please contact:

Daniel Rudeklint, Interim CEO, Peptonic Medical AB

Email: daniel.rudeklint@peptonicmedical.se

Telephone: +46 73 158 02 73

About Peptonic Medical AB

Peptonic Medical AB (publ) is a Swedish medical technology company that develops and sells clinically proven self-care products for women’s intimate health. Under the VagiVital and Vernivia brands, the Company offers a range of over-the-counter, effective and gentle products that help women understand, treat and prevent common medical conditions in the intimate area. Peptonics’ growth strategy is based on geographical expansion, particularly in the US and Europe, and on continuously strengthening the product portfolio through in-house product development and strategic acquisitions.

Translated with DeepL.com (free version)